Global MEK Inhibitors Market, Drug Sales and Clinical Trials insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 4 Drugs
- Approved MEK Drug Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-mek-map-kinase-inhibitor-market-size-clinical-trials-report
Since past few years, there have been drastic changes in the paradigm of cancer treatment with the rapid approval of several targeted drugs. Among all targeted therapies, small molecule inhibitors have gained considerable momentum in the market owing to their small size, high penetrability and targetability towards the cancer cells. Recently, researchers have developed MEK inhibitors which works by targeting the mitogen activated protein kinase (MAPK) pathway. Dysregulation and overactivation of MAPK pathway occurs in almost one-third of malignancies, thus making it potential target for the drug development process.
To date, four MEK inhibitors have been approved including Mekinist, Cotellic, Mektovi and Koselugo which have major role in the treatment of BRAF mutated melanoma patients. Their introduction into the market has shown high adoption rates by patients owing to their high specificity, targetability, and ability to overcome the limitations of conventional cancer therapies. To further enhance their efficacy in the management of cancer, these drugs are mainly used in combination with BRAF inhibitors. The combinational therapy helps to simultaneously inhibit the BRAF kinase as well as MEK1/MEK2 activity.
Currently, the market is mainly dominated by Mekinist which is mainly due to its widespread use in the management of multiple cancers including melanoma, thyroid and non-small cell lung cancer. Nevertheless, the robust response of these drugs in the market has drawn attention of various research institutions towards this sector. Several studies are on-going which are evaluating the role of these drugs in combination with other cancer targeting regimes including immunotherapy, EFGR inhibitors, chemotherapy, and other tyrosine kinase inhibitors. In addition to this, researchers are also evaluating the role of approved MEK inhibitors in other cancers including breast cancer, pancreatic cancer, ovarian cancer, and several others.
Apart from this, major pharmaceutical giants have adopted strategies including partnership, joint venture, collaborations and other to increase the investment in this sector. The key players in the global MEK inhibitor market are AstraZeneca, Pfizer, Cstone Therapeutics, Ono Pharmaceuticals, NFlection, and Roche. Te extensive efforts by the researchers and the huge investment by pharmaceutical giants have led to the development of robust pipeline of MEK inhibitors which are expected to gain approval in forthcoming years, thus boosting the growth of market.
The global MEK inhibitor market was valued at US$ XX Million in 2020 and is expected to witness high growth rates during the coming years. The increase in prevalence of melanoma and other cancers is expected to fuel the MEK inhibitor market. Apart from this, continuous clinical trials and studies on MEK inhibitors as a new treatment in the field of oncology is expected to propel the market during the forecast period. In addition, their limited adverse effects and higher efficiency of MEK inhibitors will also increase their demand in the market. As per report findings, the global MEK inhibitor market is estimated to surpass USD 3 Billion by 2026.
Regionally, North America dominated the MEK inhibitor market with a share of more than 40%, followed by Europe. US held the major revenue share in the North America region. This is owing to rising awareness among population regarding cancer and the availability of targeted therapies. In addition, rising support from government and availability of favorable reimbursement policies in the region has boosted the growth of the market in this region. The Asia-Pacific region is analyzed to grow at high CAGR rates attributing mainly to increase healthcare spending, large population base, and presence of large number of clinical research organizations.
Contact:
Neeraj Chawla
Research Head
neeraj@kuickresearch.com
+91-9810410366